Capucine Baldini

Capucine Baldini

Medical Oncologist

Gustave Roussy

France, Villejuif

Present Title & Affiliation

  • Full Attending Physician and Assistant Professor, Drug Development Department (DITEP), Gustave Roussy – 1st European Cancer Center
  • Head, GERICO (French Geriatric Oncology Clinical Research Group), UNICANCER Group (2022–Present)
  • Board Member, French Society of Geriatric Oncology (2021–Present)
  • Board Member, ESMO/SIOG Working Group (2020–Present)
  • PhD Candidate, Université Paris Saclay – LIO Laboratory (2021–2024)
  • In process of obtaining Texas Medical License and Board Certification
YearsDegree / ProgramInstitution & Location

Education & Training
2021 – 2024PhD, Cancer Biology – Clonal Hematopoiesis and Immune Senescence in Cancer Patients Treated with Immune Checkpoint InhibitorsUniversité Paris Saclay – Doctoral School of Oncology (Thesis Directors: Pr Massard & Pr Chaput)
2012 – 2013Master’s Degree in Cancer BiologyUniversity Paris-Sud XI, France
2001 – 2014MD, Medical Oncology – Thesis: “Biological Characteristics of Older Localized Breast Cancer Patients”University of Lille II, France / Université Paris V (preclinical and bachelor cycles)

Clinical Experience
2016 – PresentMedical Oncologist and Assistant Professor, Drug Development Department (DITEP)Gustave Roussy, Villejuif, France
2019 – PresentFull Attending Physician, Assistant ProfessorGustave Roussy, Villejuif
2020 – 2025Head of Outpatient Unit, Drug Development Department (DITEP)Gustave Roussy
2016 – 2017Assistant ProfessorUniversity Paris Saclay
2014 – 2016Assistant Professor, Department of OncologyUniversity Hospital of Lille, France
2011 – 2012Medical Oncology Resident, Drug Development Department (DITEP)Gustave Roussy
2008 – 2014Medical Oncology ResidencyUniversity of Lille II, France — Rotations in Oncology, Hematology, Radiation Therapy, and Geriatrics

Clinical Research Activity
Principal Investigator> 20 Phase I trials including Bispecific CD3 KLK2 (78278343PCR1001), Isatuximab ± Atezolizumab (ACT15377), EP4 antagonist (AN0025S0103), BT8009-100 (Bicyclic ADC), MK3475-365 (Pembrolizumab combinations), Keynote 158, RMC-LUNG-101 (KRAS inhibitor), LOXO ADC trials (Nectin-4) etc.
Sub-Investigator80 Phase I, 2 Phase II, and 5 Phase III studies
Consultant ExpertiseJanssen, Bicycle Therapeutics, MOMA Therapeutics, Cytea, Fasten; Venture Partner at Elaia
Grant ReviewerPHRC (Ministry of Health), Rising Foundation, UNCAN, ANR, SIOG Treviso, Swiss Grant Agencies

Accepted Abstracts at International Meetings (Selected, out of 50+)
ESMO 2024Assessing care complexity in remote patient monitoring (RPM): A cohort of 2434 cancer patients across 50 sites in France and BelgiumC. Baldini, T. Grellety, R. Boulahssass, P. Soubeyran, E.G.C. Brain, L. Mourey, C. Dumas-Bonnetain, F. Canouï-Poitrine, R. Rivoirard, A. Diab, et al.
ESMO 2024Deployment of remote patient monitoring in older patients: Real-world experience from 2419 patients across 58 centres in France and BelgiumN. Bertrand, T. Grellety, M. Autheman, R. Rivoirard, R. Boulahssass, E.G.C. Brain, L. Mourey, C. Dumas-Bonnetain, P. Caillet, M. Frelaut, C. Baldini, et al.
AACR 2024Clonal Hematopoiesis of indeterminate potential (CHIP) in patients with advanced solid tumors treated with immune checkpoint blockers (ICB): The PREMIS studyJ. Rodriguez, F.X. Danlos, A. Larive, A. Marabelle, Y. Loriot, C. Robert, L. Albiges, M. Frelaut, M. Aldea, C. Baldini, et al.
AACR 2024Subcutaneous fat mass predicts progression-free survival in patients treated with antibody-drug conjugates in early-phase clinical trialsM. Delaye, L. Lawrance, Y. Belkouchi, F. Wirth, K. Ouali, N. Lassau, S. Ammari, C. Baldini, et al.
Duravelo-1 / ESMO 2024Evaluation of an additional NSCLC cohort in the Phase 1/2 Duravelo-1 study of zelenectide pevedotin (BT8009), a Bicycle® Drug ConjugateC. Baldini, L. Verlingue, A. Italiano, L. Carter, G.S. Falchook, M. McKean, et al.
Duravelo-1 / ESMO 2024Enhanced anti-tumor activity of zelenectide pevedotin in NSCLC with NECTIN4 gene amplificationL. Verlingue, N. Klümper, M. Eckstein, M. McKean, A. Italiano, C. Baldini, et al.
ASCO 2023Clonal hematopoiesis mutations in patients with advanced solid tumors enrolled in phase I clinical trialsJ. Rodriguez, A. Bayle, F.X. Danlos, D. Vasseur, C. Marzac, C. Baldini, et al.
ASCO 2023T-cell engager (TCE) score in patients treated with bispecific CD3 TCEs in phase I trialsN. Herbel, V. Goldschmidt, J.M. Michot, A. Laparra, S. Champiat, C. Baldini, et al.
ASCO 2023Frailty IO: Frailty parameters and immune-related adverse events in older patients on immune checkpoint blockadeC. Baldini, B. Beauplet, L. Seknazi, A. Pages, M. Vanneste, et al.
AACR 2023Molecular landscape of clonal hematopoiesis in lung cancer: First results of the CHIC studyM. Tagliamento, C. Marzac, M. Aldea, B. Besse, C. Baldini, et al.
IASLC 2023Stereotactic radiotherapy improves disease control in oligoprogressive NSCLC patients in early clinical trialsA. Mavrikios, C. Baldini, Y. Loriot, S. Champiat, et al.
SABCS 2022COBRA: Characteristics and Outcomes of breast cancer patients in phase I trials at Gustave RoussyL. Seknazi, A. Geraud, V. Goldschmidt, C. Baldini, et al.
ASCO GU 2023BT8009-100: Phase I/II study of novel bicyclic peptide and MMAE conjugate BT8009 in nectin-4 positive malignanciesC. Baldini, V. Goldschmidt, I. Brana, B. Doger, A. Italiano, et al.
ASCO GU 2023Androgen receptor (AR) mutations in mCRPC: Incidence and natural historyA. Bernard-Tessier, G. Mulier, P. Nay, C. Baldini, K. Fizazi, et al.
ESMO GYN 2023Outcomes of gynecologic tumors harboring HER2 defects: Single-center molecular analysisC. Roussel-Simonin, F. Blanc-Durand, A. Bayle, C. Baldini, A. Leary, P. Pautier, et al.
ESMO 2023BRCA2 pathogenic variants as agnostic biomarkers for immune checkpoint blockadeB. Alonso de Castro, M.I. Gomez Randulfe, C. Baldini, S. Champiat, et al.
ESMO 2022High prevalence of CHIP mutations in elderly patients with solid tumorsJ.E. Rodriguez, A. Bayle, C. Baldini, et al.
ESMO 2022Prognostic markers in patients receiving bispecific T-cell engagers in phase I trialsM.T. Cunha, S. Ammari, C. Baldini, et al.
ESMO 2022Circulating tumor DNA in advanced prostate cancer: High bTMB focusZ. Guillaume, A. Bayle, L. Lacroix, C. Baldini, A. Bernard-Tessier, et al.
ASCO GU 2022Phase I results of ODM-208 (first-in-human trial in mCRPC)K. Fizazi, N. Cook, C. Baldini, et al.
ESMO 2021Pembrolizumab + Nintedanib in advanced mesothelioma (PEMBIB trial)C. Baldini, F.X. Danlos, A. Marabelle, C. Massard, et al.
ESMO 2021Molecular testing in older patients with advanced NSCLCT. Lamy, B. Cabarrou, D. Planchard, C. Baldini, et al.
TAT 2021Toxicity profile of immune vs non-immune therapies in early trialsL. Missri, P. Martin-Romano, C. Baldini, et al.
ESMO 2020Outcome of older cancer patients infected with COVID-19 at Gustave RoussyM. Hauchecorne, C. Baldini, S. Foulon, F. Scotté, B. Besse, et al.
ESMO IO 2019Applicability of LIPI score in metastatic mTNBC treated with ICIsA. Vozy, A. Simonaggio, L. Mezquita, C. Baldini, et al.
ESMO 2018Incidence of immune-related adverse events in ≥70-year-old patients on anti-PD-(L)1C. Baldini, P. Martin-Romano, F.X. Danlos, C. Massard, et al.
AACR 2018Safety and efficacy of Nintedanib + Pembrolizumab in advanced solid tumorsA. Varga, C. Baldini, A. Marabelle, J.C. Soria, et al.
ESMO 2012Tumor characteristics, treatment and survival in breast cancer > 80 yearsC. Baldini, A. Donnadieu, J. Bonneterre, et al.
ASCO 2010Nasal septum perforations with bevacizumab + taxanes in breast cancerC. Baldini, A. Mailliez, V. Servent, J. Bonneterre, et al.

Translational Research

  • Member, Immunomonitoring in Oncology Lab (LIO) – UMS CNRS 3655 & INSERM US23 AMMICa (Pr Chaput, Gustave Roussy)
  • PhD Research Project: Clonal Hematopoiesis and Immune Senescence in Cancer Patients Treated with Immune Checkpoint Inhibitors
  • Experienced in Grant Proposal and Project Writing

Mentoring & Supervision

Medical Thesis Supervision

  • Dr Monica Pierro (2021): Predicting Immunotherapy Outcomes in Older Patients Using the LIPI Score
  • Dr Samuel Olivier (2018): Early Detection of Breast Cancer in Older Patients

Thesis Jury Participation

  • Dr Zoe AP-Thomas (2021) – GRADE Score and Postoperative Mortality
  • Dr Constance Reichert (2023) – Nivolumab + Ipilimumab in Octogenarian/Nonagenarian Melanoma
  • Dr Paul Matte (2024) – Primary Resistance to ICIs in Phase I Trials

PhD Defence Jury

  • Dr Marc-Antoine Benderra (2024): Comorbidities and Chemotherapy Toxicity in Older Patients

Other Trainees

  • Master Student (2022): Noé Herbel – Use of Grim Score with T-Cell Engager
  • DUERTECC Students: W. Boulfoul (Morocco), J. Rodriguez (Argentina), L. Rached (Lebanon), R. Amine (Lebanon)
  • ESMO Fellowships: A. Vaz Ferreira (Portugal), I. Akbıyık (Turkey), M. Wilk (Poland), K. Demegillo (Philippines), N. Gkolemi (Greece)
  • Mentoring Award: L. Verlingue – Force 1 Masterclass in Clinical Research (First Prize)

Teaching Activity

At Gustave Roussy:

  • Masterclass on Chemotherapy (2017 – Present)
  • Masterclass on Prostate Cancer (2018)
  • Clinical Research in Geriatric Oncology (2023 – Present)
  • DITEP Resident and Nurse Programs (2017 – Present)

University Teaching:

  • Surgical Techniques Master (Paris Sud University, 2018)
  • Coordination & Precision Medicine University Diplomas (Paris Saclay University, 2018–2024)
  • Neuro-Oncology Diploma (Paris Saclay University, 2019)
  • Geriatric Oncology Diploma (Paris Cité University, 2019–Present)
  • Geriatrics Diploma (Lille II / Paris VI, 2018–2021)
  • Medical Oncology Diploma (Paris Saclay, 2020–2024)
  • GU Oncology and Clinical Research Diplomas (2019)

ESMO & National Courses:

  • ESMO Preceptorship in Geriatric Oncology (2022–2023)
  • AERIO Course (April 2024): Immunotherapy in Older Patients and Immunosenescence
  • National Course (May 2025): Oncologic Treatment of Older Patients

Symposia & Program Organization:

  • University Diploma in Precision Medicine (2021–2024)
  • Module in Health Engineering Diploma (IFSBM, 2021–Present)
  • Therapeutic Innovation in Oncology Module (2022–Present)
  • Masterclass of Clinical Research in Geriatric Oncology (National Society of Geriatric Oncology + Gustave Roussy, since 2023)

Scientific Communications

Oral Presentations (International Academic Events):
  • SIOG 2015 – Tolerance and Efficacy of FOLFIRINOX in Elderly Patients with Advanced Pancreatic Cancer. First Author
  • ASCO 2018 – Feasibility and Benefit of Molecularly Informed Enrollment into Early-Phase Trials for Recurrent Gliomas. First Author
  • SIOG 2018 – Incidence of irAEs in Older Patients Treated with Anti–PD-(L)1. First Author
  • EANO 2019 – Guided Enrollment of Patients with Recurrent Gliomas in Early Clinical Trials. First Author
  • SIOG 2019 – Association of LIPI Score with Immunotherapy Outcomes in Elderly Patients. First Author
  • ESMO 2019 – Precision Medicine for Primary Brain Tumors (MOSCATO Trial). Last Author
  • SIOG 2021 – Molecular Testing in Older Patients with Advanced NSCLC. Last Author
  • ESMO 2021 – Pembrolizumab and Nintedanib in Advanced Mesothelioma.
  • SNO 2022 – Pembrolizumab Monotherapy for MSI-H/dMMR Recurrent Gliomas (KEYNOTE-158). First Author
  • ESMO TAT 2024 – Subcutaneous Fat Mass Predicts PFS in ADC-treated Patients in Early Trials. Last Author
  • ASCO 2025 – Phase I Results of Pasritamig (JNJ-78278343) in Metastatic Castration-Resistant Prostate Cancer.

Invited Speaker (International Events):

  • IGOM 2017 – Setting Up a Geriatric Oncology Unit
  • MAO 2019 – Early Phase Clinical Trials in Older Patients
  • SoFOG 2018–19 – Immunotherapy in Older Patients
  • ANOCEF 2019 – Targeted Therapies in Gliomas
  • ESMO Asia 2019 – ICB Toxicities in Older Patients
  • UK Oncology Forum 2023 – Innovative Trials in Geriatric Oncology
  • GETUG 2023 – Immunotherapy in Older Patients with Cancer
  • SIOG Masterclass 2023 – Innovative Designs in Geriatric Oncology
  • SIOG 2023 – Immunotherapy in Older Patients with Cancer
  • ESMO TAT 2024 – Novel Mutant-Selective EGFR/HER2 Inhibitors – Insights and Perspectives
  • ESMO TAT 2024 – Invited Discussant
  • MAO 2025 – ADC and Immunotherapy in Older Patients
  • IFODS 2025 – Innovative Therapies in Older Patients
  • Polish Young Oncologist Forum 2025 – Clinical Trials in Geriatric Oncology

RECENT PUBLICATIONS

1. Yap TA, Rixe O, Baldini C, et al. First-in-human phase 1 study of KHK2455 monotherapy and in combination with mogamulizumab in patients with advanced solid tumors. Cancer. 2025 Jul 1;131(13):e35939.

2. Stein MN, Vinceneux A, Robbrecht D, et al. Pasritamig, a first-in-class bispecific T-cell engager targeting human kallikrein-2 in metastatic castration-resistant prostate cancer: a phase I study. J Clin Oncol. 2025 Jun 1:JCO2500678.

3. Vaz Ferreira A, Delaye M, Pages A, et al. Age does not affect the efficacy of antibody-drug conjugates but is associated with high-grade adverse events in early-phase cancer trials. Drugs Aging. 2025 Jun;42(6):583-589.

4. Guerin A, Ap Thomas Z, Nagera-Lazarovici C, et al. Comprehensive geriatric assessment and early treatment failure in nonagenarian cancer patients: a retrospective monocentric study. Cancer Epidemiol. 2025 Apr 26;97:102830.

5. Baldini C, Porte M, Rouleau E, Touat M. Liquid biopsy in gliomas—are we there yet? Ann Oncol. 2025 Jun;36(6):606-608.

6. Doublet S, Pagès A, Thomas ZA, et al. Systemic treatment among frail older patients with cancer: an observational cohort. J Geriatr Oncol. 2025 Mar;16(2):102177.

7. Guerra M, Alouani E, Hueso T, et al. Relevance, risks, and benefits of early-phase clinical trial participation in hematologic malignancies (2008–2023). Eur J Haematol. 2025 Jan;114(1):89-97.

8. Paillaud E, Galvin A, Doublet S, et al. Health literacy and use of digital tools in older versus younger cancer patients: a multicenter nationwide study. Patient Educ Couns. 2025 Jan;130:108420.

9. Loh KP, Liposits G, Arora SP, et al. Adequate assessment yields appropriate care: the role of geriatric assessment and management—position paper from ESMO/SIOG. ESMO Open. 2024 Aug;9(8):103657.

10. Mathiot L, Baldini C, Letissier O, et al. Target expression and treatment efficacy of antibody-drug conjugates in solid cancers: a comprehensive review. Curr Oncol Rep. 2024 Jul 27.

11. Rodriguez J*, Baldini C*, Bayle A, et al. Clonal hematopoiesis-associated mutations and outcomes in phase I solid tumor patients (STING trial). JCO Precis Oncol. 2024 May;8:e2300631.

12. Géraud A, Hueso T, Laparra A, et al. Reactions and adverse events induced by T-cell engagers in cancer immunotherapy: a comprehensive review. Eur J Cancer. 2024 Jul;205:114075.

13. Rached L, Laparra A, Sakkal M, et al. Toxicity of immunotherapy combinations with chemotherapy across tumor types: current knowledge and recommendations. Cancer Treat Rev. 2024 Jun;127:102751.

14. Corbaux P, Bayle A, Besle S, et al. Patient selection and trial matching in early-phase oncology trials. Crit Rev Oncol Hematol. 2024 Apr;196:104307.

15. Fizazi K, Bernard-Tessier A, Roubaud G, et al. Targeted inhibition of CYP11A1 in castration-resistant prostate cancer.NEJM Evid. 2024 Jan;3(1).

16. Rodriguez JE, Micol JB, Baldini C. Exploring clonal hematopoiesis and its impact on aging, cancer, and patient care.Aging (Albany NY). 2023 Dec 20;15(24):14507-14508.

17. Rached L, Geraud A, Frelaut M, et al. Antibody-drug conjugates in older patients: state of the art. Crit Rev Oncol Hematol. 2024 Jan;193:104212.

18. Rached L, Frelaut M, Baldini C. Bridging the gap: addressing disparities in clinical trial access among geriatric oncology patients. ESMO Open. 2023 Dec;8(6):102029.

19. Alouani E, Laparra A, Perret A, et al. Mycophenolate mofetil for steroid-refractory immune-related hepatitis induced by checkpoint inhibitors. Eur J Cancer. 2023 Nov;193:113313.

20. Reichert C, Baldini C, Mezghani S, et al. Combined nivolumab and ipilimumab in octogenarian and nonagenarian melanoma patients. Cancers (Basel). 2023 Aug 30;15(17):4330.

21. Galvin A, Bertrand N, Boulahssass R, et al. Rethinking care management for older adults with cancer: proposals from the PRIORITES AGE CANCER group. J Geriatr Oncol. 2024 Jan;15(1):101608.

22. Charton E, Baldini C, Fayet Y, et al. Inequality factors in access to early-phase oncology trials in France: EGALICAN-2 study. ESMO Open. 2023 Aug;8(4):101610.

23. Valery M, Saleh K, Ecea R, et al. Infections after IL-6 blockade for cytokine release syndrome in onco-hematology patients. Cancer Chemother Pharmacol. 2023 Sep;92(3):229-233.

24. Martinez-Tapia C, Rougette K, Fossey-Diaz V, et al. Prevalence of sarcopenia criteria and predictive value for 6-month mortality: NutriAgeCancer cohort. Nutrients. 2023 Mar;15(6):1508.

25. Couderc AL, Liuu E, Boudou-Rouquette P, et al. Pre-therapeutic sarcopenia in cancer patients: updated meta-analysis of prevalence and prognostic value. Nutrients. 2023 Feb;15(5):1193.

26. Mebarki S, Pamoukdjian F, Pierro M, et al. Safety and efficacy of immunotherapy in patients aged ≥80 years. Bull Cancer. 2023 Mar.

27. Danlos FX, Texier M, Job B, et al. Genomic instability and inflammation as drivers of resistance to anti-PD-1 + anti-angiogenesis in mesothelioma. Cancer Discov. 2023 Apr;13(4):858-879.

28. Bringuier M, Carton M, Debieuvre D, et al. Enrollment of older adults with advanced NSCLC in first-line trials: ESME cohort. J Geriatr Oncol. 2023 Mar;14(2):101423.

29. Martin-Romano P, Mezquita L, Hollebecque A, et al. Implementing ESMO Scale of Clinical Actionability in precision oncology programs. JCO Precis Oncol. 2022 Oct;6:e2100484.

30. Pierro M, Baldini C, Auclin E, et al. Predicting immunotherapy outcomes in older patients using the LIPI score.Cancers (Basel). 2022 Oct;14(20):5078.

31. Hilmi M, Naoun N, Boilève A, et al. Supportive care needs, sexuality, and QoL in phase I oncology trials. Support Care Cancer. 2022 Oct.

32. Di Stefano AL, Nichelli L, Berzero G, et al. In vivo 2-hydroxyglutarate monitoring with MR spectroscopy in IDH-mutant gliomas (IDASPE study). Neurology. 2022 Sep.

33. Hilton J, Cristea M, Postel-Vinay S, et al. BMS-986158, a BET inhibitor, in advanced solid tumors: phase 1/2a results.Cancers (Basel). 2022 Aug;14(17):4079.

34. Ouali K, Mateus C, Laparra A, et al. PALLIA-10 score in phase I cancer studies. BMJ Support Palliat Care. 2022 Aug.

35. Martin-Romano P, Colmet-Daage L, Morel D, et al. Epigenetic alterations in metastatic solid tumors: results from MOSCATO & MATCH-R. Eur J Cancer. 2022 Sep;173:133-145.

36. Rodriguez JE, Naigeon M, Goldschmidt V, et al. Immunosenescence, inflammaging, and cancer immunotherapy efficacy. Expert Rev Anticancer Ther. 2022 Sep;22(9):915-926.

37. Baldini C, Danlos FX, Varga A, et al. Nintedanib + pembrolizumab in advanced cancers: safety, efficacy, and immune correlates. J Exp Clin Cancer Res. 2022 Jul 7;41(1):217.

38. Tselikas L, Dardenne A, de Baere T, et al. Feasibility and efficacy of intratumoral immunotherapy: Gustave Roussy’s initial 100 patients. Eur J Cancer. 2022 Sep;172:1-12.

39. Galvin A, Bertrand N, Boulahssass R, et al. [Rethinking management of elderly cancer patients: Age Cancer Priorities Group]. Bull Cancer. 2022 Jun;109(6):714-721.

40. Baldini C, Charton E, Schultz E, et al. Access to early-phase clinical trials in older patients (EGALICAN-2, France).ESMO Open. 2022 May;7(3):100468.

41. Tagliamento M, Frelaut M, Baldini C, et al. Use of immunotherapy in older patients with advanced NSCLC. Cancer Treat Rev. 2022 May;106:102394.

42. Bringuier M, Carton M, Levy C, et al. Enrollment of older metastatic breast cancer patients in first-line clinical trials: ESME cohort. Breast Cancer Res Treat. 2022 Feb;191(3):577-587.

43. Guiard E, Baldini C, Pobel C, et al. Radiologic progression patterns under ICI + anti-angiogenic therapy. Eur J Cancer. 2022 May;167:42-53.

44. Baldini C, Younan N, Castanon E, et al. Genome-driven medicine for recurrent glioma patients in early trials. Eur J Cancer. 2022 Mar;163:98-107.

45. Yap TA, Vieito M, Baldini C, et al. First-in-human phase I study of LY3200882, an oral TGFβR1 inhibitor. Clin Cancer Res. 2021 Sep 21.

46. Bayle A, Baldini C, Martin-Romano P, et al. Sustained clinical trial activity in a French hospital during COVID-19.Cancer Cell. 2021 Aug 9;39(8):1039-1041.

47. Berzero G, Bellu L, Baldini C, et al. Sustained tumor control with MAPK inhibition in BRAF V600-mutant glial tumors. Neurology. 2021 Aug.

48. Helissey C, Geiss R, Baldini C, et al. Why and how to assess older people with cancer? Bull Cancer. 2021 May;108(5):513-520.

49. de’Angelis N, Baldini C, Brustia R, et al. Correction: surgical and regional treatments for CRC metastases in older patients. PLoS One. 2021 Apr.

50. Azaro A, Baldini C, Rodon J, et al. Phase I study of crenigacestat (LY3039478) + prednisone in advanced cancer.Invest New Drugs. 2021 Feb;39(1):193-201.

51. Bernard-Tessier A, Baldini C, Castanon E, et al. Patterns of progression with immune checkpoint + anti-angiogenic combinations. Cancer Immunol Immunother. 2021 Jan;70(1):221-232.

52. Laparra A, Kfoury M, Champiat S, et al. Multiple immune-related toxicities as surrogate markers in ICI trials.Unpublished conference communication, 2021.

53. Hauchecorne M, Pierro M, Brain E, et al. Perspectives on cancer care in older patients in France.Ecancermedicalscience. 2020 Sep 15;14:1103.

54. De Giglio A, Nuvola G, Baldini C. Combination therapies in advanced NSCLC: age, ECOG PS 2, steroids, and antibiotics. Future Oncol. 2020 Aug;16(23):1683-1690.

55. Battisti NML, Liposits G, De Glas NA, Gomes F, Baldini C, Mohile S. Systemic therapy of common tumors in older patients: challenges and opportunities. Curr Oncol Rep. 2020 Jul.

56. Baldini C, Martin-Romano P, Voisin AL, et al. Impact of aging on immune-related adverse events generated by anti–PD-(L)1 therapies. Eur J Cancer. 2020 Apr;129:71–79.

57. de’Angelis N, Baldini C, Brustia R, et al. Surgical and regional treatments for colorectal cancer metastases in older patients: a systematic review and meta-analysis. PLoS One. 2020 Apr. Erratum in: PLoS One. 2021 Apr 27.

58. Touat M, Li YY, Boynton AN, et al. Mechanisms and therapeutic implications of hypermutation in gliomas. Nature.2020 Apr;580(7804):517–523.

59. Martin-Romano P, Baldini C, Postel-Vinay S. How much can we bet on activity of BET inhibitors beyond NUT midline carcinoma? JNCI Cancer Spectr. 2019 Nov.

60. Mailliez A, Baldini C, Van JT, et al. Nasal septum perforation: a side effect of bevacizumab chemotherapy in breast cancer patients. Br J Cancer. 2010 Sep 7;103(6):772–775.

61. Baldini C, Duchemann B, Hollebecque A, et al. Focus on targeting the Ras-MAPK pathway: MEK inhibitors. Bull Cancer. 2012;99(9):865–874.

62. Ploquin A, Baldini C, Vuagnat P, et al. Prolonged survival in a patient with pancreatic acinar cell carcinoma. Case Rep Oncol. 2015;8(3):447–450.

63. Payen T, Dizeux A, Baldini C, et al. VEGFR2-targeted contrast-enhanced ultrasound to distinguish between two anti-angiogenic treatments. Ultrasound Med Biol. 2015;41(8):2202–2211.

64. Baldini C, Escande A, Bouché O, et al. Safety and efficacy of FOLFIRINOX in elderly patients with metastatic or locally advanced pancreatic cancer: a retrospective analysis. Pancreatology. 2017 Jan–Feb;17(1):146–149.

65. Mislang AR, Wildes TM, Kanesvaran R, et al. Adherence to oral cancer therapy in older adults: SIOG taskforce recommendations. Cancer Treat Rev. 2017 Jun;57:58–66.

66. Baldini C, Le Saux O, Helissey C, et al. Are phase I trials safe for older patients? J Geriatr Oncol. 2017 Sep 7.

67. Bigot F, Castanon E, Baldini C, et al. Prospective validation of the Gustave Roussy Immune Score (GRIm-Score) in immunotherapy phase I trials. Eur J Cancer. 2017;84:212–218.

68. Sun R, Champiat S, Dercle L, et al. Baseline lymphopenia should not exclude patients from early PD-1/PD-L1 trials.Eur J Cancer. 2017;84:202–211.

69. Ploquin A, Truant S, Piessen G, et al. Predictive factors for prolonged survival under gemcitabine in pancreatic adenocarcinoma. In Vivo. 2017;31(4):731–735.

70. Benajiba L, Michot JM, Baldini C, et al. Prognostic factors and outcomes in hematologic malignancies: the Gustave Roussy phase I score. Anticancer Drugs. 2017;28(5):540–545.

71. Loh KP, Soto-Perez-de-Celis E, Hsu T, et al. What every oncologist should know about geriatric assessment. J Oncol Pract. 2018 Feb;14(2):85–94.

72. Herin H, Aspeslagh S, Castanon E, et al. Immunotherapy phase I trials in patients aged ≥70 years with advanced solid tumors. Eur J Cancer. 2018 May;95:68–77.

73. Bernard-Tessier A, Baldini C, Martin P, et al. Rechallenge with anti–PD-1/PD-L1 in long-term responders after progression. Eur J Cancer. 2018 Sep.

74. Soto-Perez-de-Celis E, Loh KP, Baldini C, et al. Targeted agents for HER2-positive breast cancer in older adults: current and future perspectives. Expert Opin Investig Drugs. 2018 Oct;27(10):787–804.

75. Watson S, Menis J, Baldini C, et al. Time-to-progression ratio in early-phase clinical trials: time for new guidelines?Br J Cancer. 2018 Oct;119(8):937–939.

76. Baldini C, Romano PM, Varga A, et al. Immunothérapie des glioblastomes. Bull Cancer. 2018 Dec;105 Suppl 1:S59–S67.

77. Gravis G, Billon E, Baldini C, et al. Unexpected response to cisplatin rechallenge after immune checkpoint blockade in urothelial carcinoma. Eur J Cancer. 2018;104:236–238.

78. Michot JM, Benajiba L, Faivre L, et al. Outcomes and prognostic factors for relapsed/refractory lymphoma in phase I trials. Invest New Drugs. 2018;36(1):62–74.

79. Besle S, Schultz E, Hollebecque A, et al. Organizational factors influencing early clinical trial enrollment: Gustave Roussy experience. Eur J Cancer. 2018;98:17–22.

80. Cabel L, Fuerea A, Lacroix L, et al. Histology-agnostic HER2 inhibitors for refractory cancers. Oncotarget.2018;9(11):9741–9750.

81. Verlingue L, Hollebecque A, Lacroix L, et al. HER family inhibitors in ERBB3-mutated cancers: entering the back door. Eur J Cancer. 2018;92:1–10.

82. Gauci ML, Lanoy E, Champiat S, et al. Long-term survival and disease outcome after discontinuation of anti–PD-1/PD-L1 therapy. Clin Cancer Res. 2019 Feb 1;25(3):946–956.

83. Baldini C, Mourey L, Liposits G. Perspectives on geriatric oncology research at ESMO 2018: Young SIOG report. J Geriatr Oncol. 2019 Mar;10(2):183–185.

84. Liposits G, Loh KP, Soto-Perez-de-Celis E, et al. PARP inhibitors in older patients with ovarian and breast cancer. J Geriatr Oncol. 2019 Mar;10(2):337–345.

85. Baldini C, Champiat S, Vuagnat P, et al. Durvalumab for urothelial carcinoma: emerging data and potential. Onco Targets Ther. 2019 Apr;12:2505–2511.

86. Bastiaannet E, Battisti NML, Loh KP, et al. Immunotherapy and targeted therapies in older patients with advanced melanoma. J Geriatr Oncol. 2019 May;10(3):389–397.

87. Michot JM, Fusellier M, Champiat S, et al. Drug-induced lupus erythematosus following anti–PD-(L)1 immunotherapy. Ann Rheum Dis. 2019 Jul.

AWARDS & GRANTS

  • Innovative Protocol Award, MCCR Workshop, 2018
  • Prix Michel Hery, 2021 (1st Prize)
  • Clinical Trials Award, Society for Neuro-Oncology (SNO), 2022

Grants:

  • Frailty Immuno Study, Bristol Myers Squibb Foundation
  • POG, French Ministry of Health (PREPS)
  • ENERGY, French Ministry of Health (PREPS)
  • PHRC-K, PREPS, French Ministry of Health
  • MSD Avenir and Fondation pour la Recherche Médicale (FRM) — submitted

BOOKS

  1. Encyclopedia of Gerontology and Population Aging (Eds. Danan Gu, Matthew E. Dupre) — Chapter: Cancer Diagnosis
  2. Springer Frailty Book — Chapter: Radiotherapy and Systemic Cancer Treatment
  3. FROG Book — Chapter: Immunotherapy in Older Patients (2022 International Edition)
  4. Gustave Roussy Chemotherapy Masterclass, Editions 2019 / 2022 / 2025

REVIEWER FOR

European Journal of Cancer; ESMO Open; JNCI; JCO; Drugs & Aging; Journal of Gerontology & Geriatric Medicine; Cancer Immunology, Immunotherapy; BMC; Clinical Cancer Research; Lancet Oncology.

PROFESSIONAL SOCIETY MEMBERSHIPS

  • ESMO — since 2013
  • ASCO — since 2018
  • SIOG — since 2017
  • AACR — since 2017
  • SoFOG (Board Member) — since 2019
  • EORTC — since 2023
  • Young SIOG Board Member, Sep 2016 – Sep 2020
  • Founder, Young Group within the French Society of Geriatric Oncology, Sep 2018